FEB 20, 2017 10:19 AM PST

Scalp-cooling Device Gets Thumbs Up from 2 US Studies

WRITTEN BY: Xuan Pham

Although the scalp-cooling cap has been available in Europe for a number of years, the device was only approved in the US market in 2015. Now, independent results by two notable institutions in the US provide supporting evidence that the device reduces hair loss in patients undergoing chemotherapy.

Traditional cancer treatment with chemotherapy involves using highly toxic drugs to kill errant cancer cells. Because the majority of these drugs do not discriminate between cancer and normal cells, patients experience collateral damages as adverse side effects. Hair loss (alopecia) is a common side effect of certain types of chemotherapy, typically associated with treatment for breast cancer. Though considered a temporary effect, minimizing hair loss is important to the quality of life for many patients.

"Some of today's most powerful, life-saving chemotherapy treatments still cause complete hair loss, a side effect that many women consider to be emotionally devastating," said Dr. Hope Rugo, Principal Investigator for the study and Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center.

Named DigniCap, the cooling system is manufactured by Dignitana in Sweden. It works by circulating a liquid coolant to a tight-fitting silicone cap worn on the head during chemotherapy sessions. A second cap made of neoprene covers this cooling cap to act as insulation and prevent loss of cooling. The entire system is computerized with sensors that continuously monitor scalp temperature and allow the system to maintain optimal cooling throughout treatment.

The coldness of the cap acts to constrict blood vessels in the scalp, reducing blood flow to the hair follicles and protecting the hair from the flow of toxic chemotherapy agents in the body. In addition, the cooling action slows down cell division activities of the hair follicles, which makes them less susceptible to the uptake of chemotherapy drugs. These factors together reduce the risk of hair loss associated with cancer treatment.

A U.S. clinical trial studied the effects of the DigniCap in 122 women with Stage I and Stage II breast cancer who were undergoing chemotherapy. Patients then self-assessed the hair loss using standardized photographs at one month after the last chemotherapy cycle. More than 66% of these patients reported keeping at least 50% of their hair. In addition, patients reported high satisfaction for the experience: a mean of 87.5 satisfaction with the decision to use the DigniCap, a mean of 70.9 for hair quantity, and a mean of 69.1 for hair quality (ranked from 0 to 100, with 100 being “completely satisfied”). No severe adverse events were reported.

Similarly, another trial, conducted at the Baylor College of Medicine, Houston, researchers found that patients who were not treated with the device were more likely to experience up to 50 percent hair loss.

The US trials only evaluated the device on chemotherapy regimens using taxanes, such as paclitaxel and docetaxel. However, abroad the device has also been studied with anthracyclines, such as epirubicin and doxorubicin.

While the risk of the chemotherapy drug missing breast cancer cells in the scalp is considered extremely low, the benefits of the cooling cap are significant. The device minimizes the psychological impact of the diagnosis and makes the chemotherapy process more tolerable. Reducing hair loss during chemotherapy allows these patients to retain some normalcy and privacy in their lives.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 11, 2020
Clinical & Molecular DX
Smart Mask Detects COVID Infections, Sends Alert to Phone
NOV 11, 2020
Smart Mask Detects COVID Infections, Sends Alert to Phone
  This week, the Centers for Disease Control and Prevention issued new guidance to put the “mask debate&rdquo ...
NOV 16, 2020
Clinical & Molecular DX
How the CRISPR-based COVID Microlab Can Intercept the Pandemic
NOV 16, 2020
How the CRISPR-based COVID Microlab Can Intercept the Pandemic
The demand for diagnostic technologies to track COVID-19 infections and control community spread of the disease has only ...
DEC 23, 2020
Cancer
A Combination of Photo and Sonodynamic Therapies Could Assist in Treating Brain Cancer
DEC 23, 2020
A Combination of Photo and Sonodynamic Therapies Could Assist in Treating Brain Cancer
Brain cancer is an incredible challenge for modern medicine. Most drugs don’t make it past the blood-brain barrier ...
JAN 12, 2021
Clinical & Molecular DX
Portable Sequencer Ensures All the Cancer Cells Are Gone
JAN 12, 2021
Portable Sequencer Ensures All the Cancer Cells Are Gone
Surgeons remove a tumor from the abdominal cavity of a patient. But how can they be certain that all the cancer cells we ...
FEB 11, 2021
Clinical & Molecular DX
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
FEB 11, 2021
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
Only around half of women diagnosed with breast cancer will benefit from hormonal therapy, a cancer treatment that adds, ...
FEB 25, 2021
Coronavirus
COVID Long-Haulers Get Official Recognition
FEB 25, 2021
COVID Long-Haulers Get Official Recognition
For months, many people that have recovered from cases of COVID-19 have reported experiencing a range of lingering healt ...
Loading Comments...